{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:00:10Z","timestamp":1794031210401,"version":"4.8.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Xanthomatosis is a genetic disease inherited in an autosomal recessive manner. The specific phenotypic features are associated with patient\u2019s genetic profile. The result of the mutation is disorder of cholesterol synthesis and the accumulation of its precursors in tissues. The characteristic symptoms are progressive cerebellar ataxia, cataract, diarrhea, and the deposition of cholesterol in the tendons. Our objective is to follow-up information to treatment efficacy of 22-year-old patient diagnosed with cerebrotendinous xanthomatosis through 1.5\u2009year observation. In 2012, an 11-year-old patient with a long history of deformed feet and frequent yellowing of the skin, was admitted to the Department of Neurology due to seizures. In 2013, the patient began to suffer from diarrhea, and its frequency was correlated with the concentration of bilirubin in the blood. In the same year cataract was diagnosed. Gradually, the patient starts to complain about progressive difficulties in moving. In 2019, genetic tests confirmed the diagnosis of cerebrotendinous xanthomatosis. Since July 2021, the patient has been treated with chenodeoxycholic acid. The deterioration of patient\u2019s mobility has been significantly inhibited, consequently his quality of life has improved. The presented case report underscores the efficacy of CDCA supplementation in halting the progression of CTX, resulting in marked improvements in the patient\u2019s quality of life.<\/jats:p>","DOI":"10.3389\/fneur.2024.1409138","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:43:16Z","timestamp":1718584996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Cerebrotendinous xanthomatosis treatment follow-up"],"prefix":"10.3389","volume":"15","author":[{"given":"Karolina","family":"Ejsmont-Sowa\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Ksi\u0105\u017cek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Maciorowska-Ros\u0142an","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Ros\u0142an","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Czarnowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jakubiuk-Tomaszuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Tarasiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kapica-Topczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Ku\u0142akowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40673-021-00128-2","article-title":"Cerebrotendinous Xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid","volume":"8","author":"Islam","year":"2021","journal-title":"Cerebell Ataxias"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-014-0179-4","article-title":"Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management","volume":"9","author":"Nie","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/practneurol-2020-002895","article-title":"Cerebrotendinous xanthomatosis revisited","volume":"21","author":"Baghbanian","year":"2021","journal-title":"Pract Neurol"},{"key":"ref4","article-title":"Cerebrotendinous Xanthomatosis","volume-title":"GeneReviews\u00ae","author":"Federico","year":"2023"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jmd2.12163","article-title":"Cerebrotendinous xanthomatosis-associated diarrhea and response to chenodeoxycholic acid treatment","volume":"56","author":"Brass","year":"2021","journal-title":"JIMD Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10545-013-9674-3","article-title":"A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis","volume":"37","author":"Mignarri","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01980-5","article-title":"Expert opinion on diagnosing, treating and managing patients with cerebrotendinous xanthomatosis (CTX): a modified Delphi study","volume":"16","author":"Stelten","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref8","year":"2023"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.5551\/jat.RV17055","article-title":"Cerebrotendinous xanthomatosis: molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments","volume":"28","author":"Koyama","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/cge.14079","article-title":"First case series of polish patients with cerebrotendinous xanthomatosis and systematic review of cases from the 21st century","volume":"101","author":"Badura-Stronka","year":"2022","journal-title":"Clin Genet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00415-019-09377-y","article-title":"Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults","volume":"266","author":"Mandia","year":"2019","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1049850","DOI":"10.3389\/fneur.2022.1049850","article-title":"Cerebrotendinous Xanthomatosis: a practice review of pathophysiology, diagnosis, and treatment","volume":"13","author":"N\u00f3brega","year":"2022","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1194\/jlr.M600113-JLR200","article-title":"Cholestanol metabolism in patients with cerebrotendinous xanthomatosis: absorption, turnover, and tissue deposition","volume":"48","author":"Bhattacharyya","year":"2007","journal-title":"J Lipid Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.medcli.2018.05.021","article-title":"Cerebrotendinous xanthomatosis: the diagnostic challenge","volume":"152","author":"Jaramillo","year":"2018","journal-title":"Med Clin"},{"key":"ref15","first-page":"136","article-title":"\u017b\u00f3\u0142takowato\u015b\u0107 \u015bci\u0119gnisto-m\u00f3zgowa\u2014opis przypadku","volume":"8","author":"Da\u0142ek","year":"2012","journal-title":"Polski Przegl\u0105d Neurologiczny"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s10038-017-0389-4","article-title":"Nationwide survey on cerebrotendinous xanthomatosis in Japan","volume":"63","author":"Sekijima","year":"2018","journal-title":"J Hum Genet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1176\/ajp.145.3.354","article-title":"Psychiatric disorders in patients with cerebrotendinous xanthomatosis","volume":"145","author":"Berginer","year":"1988","journal-title":"Am J Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1212\/WNL.0000000000006731","article-title":"Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start","volume":"92","author":"Stelten","year":"2019","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clineuro.2013.12.008","article-title":"Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report","volume":"118","author":"Luyckx","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3390\/biomedicines11051430","article-title":"Successful treatment of a rare cholesterol homeostasis disorder due to CYP27A1 gene mutation with Chenodeoxycholic acid therapy","volume":"11","author":"Brlek","year":"2023","journal-title":"Biomedicines"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacl.2018.06.008","article-title":"Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis","volume":"12","author":"Duell","year":"2018","journal-title":"J Clin Lipidol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10072-019-04169-8","article-title":"The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies","volume":"41","author":"Verrips","year":"2020","journal-title":"Neurol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00431-015-2584-7","article-title":"Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment","volume":"175","author":"Huidekoper","year":"2016","journal-title":"Eur J Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jacl.2023.07.002","article-title":"Treatment of cerebrotendinous xanthomatosis in pregnancy: patient and physician perspectives","volume":"17","author":"Duell","year":"2023","journal-title":"J Clin Lipidol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6947-12-78","article-title":"Querying phenotype-genotype relationships on patient datasets using semantic web technology: the example of cerebrotendinous xanthomatosis","volume":"12","author":"Taboada","year":"2012","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fgene.2020.00682","article-title":"C.1263+1G>a is a latent hotspot for CYP27A1 mutations in Chinese patients with cerebrotendinous xanthomatosis","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Genet"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1409138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:43:21Z","timestamp":1718585001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1409138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":26,"alternative-id":["10.3389\/fneur.2024.1409138"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1409138","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"article-number":"1409138"}}